We can offer pharmaceutical intermediate contract manufacturing services. With comprehensive technical expertise and current GMP facilities in China, we can provide custom synthesis for R&D and commercial scaleup of these pharmaceutical intermediates.
Paxlovid is the first oral antiviral medicine for treating COVID-19, which contains two active substances, nirmatrelvir and ritonavir. Huateng Pharma now is developing the following intermediates of Paxlovid. And, we can provide CDMO services for COVID-19 drugs with sufficient capacity.
▶ CAS NO.67911-21-1 | Caronic anhydride
▶ CAS NO.194421-56-2 | 6,6-Dimethyl-3-Azabicyclo[3.1.0]hexane-2,4-dione
▶ CAS NO.565456-77-1 | (1R,2S,5S)-Methyl 6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate hydrochloride
▶ CAS NO.943516-54-9 | 6,6-Dimethyl-3-azabicyclo[3.1.0]hexane